Literature DB >> 22271250

A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list.

Christian Toso1, Elise Dupuis-Lozeron, Pietro Majno, Thierry Berney, Norman M Kneteman, Thomas Perneger, Philippe Morel, Gilles Mentha, Christophe Combescure.   

Abstract

UNLABELLED: In many countries, the allocation of liver grafts is based on the Model of End-stage Liver Disease (MELD) score and the use of exception points for patients with hepatocellular carcinoma (HCC). With this strategy, HCC patients have easier access to transplantation than non-HCC ones. In addition, this system does not allow for a dynamic assessment, which would be required to picture the current use of local tumor treatment. This study was based on the Scientific Registry of Transplant Recipients and included 5,498 adult candidates of a liver transplantation for HCC and 43,528 for non-HCC diagnoses. A proportional hazard competitive risk model was used. The risk of dropout of HCC patients was independently predicted by MELD score, HCC size, HCC number, and alpha-fetoprotein. When combined in a model with age and diagnosis, these factors allowed for the extrapolation of the risk of dropout. Because this model and MELD did not share compatible scales, a correlation between both models was computed according to the predicted risk of dropout, and drop-out equivalent MELD (deMELD) points were calculated.
CONCLUSION: The proposed model, with the allocation of deMELD, has the potential to allow for a dynamic and combined comparison of opportunities to receive a graft for HCC and non-HCC patients on a common waiting list.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2012        PMID: 22271250     DOI: 10.1002/hep.25603

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  32 in total

Review 1.  Management of hepatocellular carcinoma.

Authors:  P Fitzmorris; M Shoreibah; B S Anand; A K Singal
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-27       Impact factor: 4.553

2.  Comparison of two equivalent model for end-stage liver disease scores for hepatocellular carcinoma patients using data from the United Network for Organ Sharing liver transplant waiting list registry.

Authors:  Sarah K Alver; Douglas J Lorenz; Kenneth Washburn; Michael R Marvin; Guy N Brock
Journal:  Transpl Int       Date:  2017-08-23       Impact factor: 3.782

Review 3.  Transplant benefit for patients with hepatocellular carcinoma.

Authors:  Alessandro Vitale; Michael Volk; Umberto Cillo
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

Review 4.  Transplantation for hepatocellular cancer: pushing to the limits?

Authors:  Quirino Lai; Alessandro Vitale
Journal:  Transl Gastroenterol Hepatol       Date:  2018-09-14

5.  Who should undergo liver transplantation for hepatocellular carcinoma? Ablate, wait … and see!

Authors:  Willscott E Naugler; Barry Schlansky; Susan L Orloff
Journal:  Hepat Oncol       Date:  2014-03-20

6.  HCC patients suffer less from geographic differences in organ availability.

Authors:  C Schuetz; N Dong; E Smoot; N Elias; D A Schoenfeld; J F Markmann; H Yeh
Journal:  Am J Transplant       Date:  2013-09-06       Impact factor: 8.086

Review 7.  Model for End-stage Liver Disease.

Authors:  Ashwani K Singal; Patrick S Kamath
Journal:  J Clin Exp Hepatol       Date:  2012-12-01

8.  Delta-slope of alpha-fetoprotein improves the ability to select liver transplant patients with hepatocellular cancer.

Authors:  Quirino Lai; Milton Inostroza; Juan M Rico Juri; Pierre Goffette; Jan Lerut
Journal:  HPB (Oxford)       Date:  2015-09-16       Impact factor: 3.647

Review 9.  Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation.

Authors:  Maurizio Pompili; Giampiero Francica; Francesca Romana Ponziani; Roberto Iezzi; Alfonso Wolfango Avolio
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

10.  Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.

Authors:  Neil Mehta; Jennifer L Dodge; Aparna Goel; John Paul Roberts; Ryutaro Hirose; Francis Y Yao
Journal:  Liver Transpl       Date:  2013-12       Impact factor: 5.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.